DSP-2230

Source: Wikipedia, the free encyclopedia.
DSP-2230
Clinical data
Routes of
administration		By mouth
Identifiers
  • (2S)-2-[[[3-cyclobutyl-5-(3,4,5-trifluorophenoxy)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]amino]propanamide
JSmol)
  • FC1=CC(OC2=CC=C(N=C3CN([C@@H](C(N([H])[H])=O)C)[H])C(N3C4CCC4)=N2)=CC(F)=C1F
  • InChI=1S/C20H20F3N5O2/c1-10(19(24)29)25-9-16-26-15-5-6-17(27-20(15)28(16)11-3-2-4-11)30-12-7-13(21)18(23)14(22)8-12/h5-8,10-11,25H,2-4,9H2,1H3,(H2,24,29)/t10-/m1/s1
  • Key:HHXCJIMPEJSJTG-SNVBAGLBSA-N

DSP-2230 is a

Dainippon Sumitomo Pharma for the treatment of neuropathic pain.[1][2] As of June 2014, it is in phase I/phase II clinical trials.[1][2]

See also

References

  1. ^
    ISSN 1945-3477
    .
  2. ^
    PMID 25060923
    .

External links

  • "DSP-2230". AdisInsight. Springer Nature Switzerland AG.